[go: up one dir, main page]

CY1111627T1 - Υποκατεστημενα γλυκιναμιδια με αντιθρομβωτικη δραση και ανασταλτικη δραση στον παραγοντα χα - Google Patents

Υποκατεστημενα γλυκιναμιδια με αντιθρομβωτικη δραση και ανασταλτικη δραση στον παραγοντα χα

Info

Publication number
CY1111627T1
CY1111627T1 CY20111100202T CY111100202T CY1111627T1 CY 1111627 T1 CY1111627 T1 CY 1111627T1 CY 20111100202 T CY20111100202 T CY 20111100202T CY 111100202 T CY111100202 T CY 111100202T CY 1111627 T1 CY1111627 T1 CY 1111627T1
Authority
CY
Cyprus
Prior art keywords
action
factor
antithrombotic
substituted glycinamides
glycinamides
Prior art date
Application number
CY20111100202T
Other languages
English (en)
Inventor
Wolfgang Wienen
Roland Pfau
Kai Gerlach
Georg Dahmann
Henning Priepke
Herbert Nar
Sandra Handschuh
Annette Schuler-Metz
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of CY1111627T1 publication Critical patent/CY1111627T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Αντικείμενο της παρούσας εφεύρεσης είναι νέα υποκατεστημένα γλυκιναμίδια του γενικού τύπου (I), στα οποία τα D, M,R3 και R5 ορίζονται όπως στην περιγραφή, τα ταυτομερή τους, τα εναντιομερή τους, τα διαστερεοϊσομερή τους, τα μείγματα τους, και τα άλατα τους, ιδιαιτέρως τα φυσιολογικά αποδεκτά άλατα τους με ανόργανα ή οργανικά οξέα ή βάσεις, τα οποία έχουν πολύτιμες ιδιότητες.
CY20111100202T 2005-06-30 2011-02-16 Υποκατεστημενα γλυκιναμιδια με αντιθρομβωτικη δραση και ανασταλτικη δραση στον παραγοντα χα CY1111627T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05014270 2005-06-30
EP06763910A EP1899330B9 (de) 2005-06-30 2006-06-28 Substituierte glycinamide mit antithrombotischer und faktor xa-inhibierender wirkung

Publications (1)

Publication Number Publication Date
CY1111627T1 true CY1111627T1 (el) 2015-10-07

Family

ID=35907001

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100202T CY1111627T1 (el) 2005-06-30 2011-02-16 Υποκατεστημενα γλυκιναμιδια με αντιθρομβωτικη δραση και ανασταλτικη δραση στον παραγοντα χα

Country Status (33)

Country Link
US (3) US20100216769A1 (el)
EP (1) EP1899330B9 (el)
JP (1) JP4768016B2 (el)
KR (1) KR101321722B1 (el)
CN (1) CN101213195B (el)
AR (1) AR054627A1 (el)
AT (1) ATE489381T1 (el)
AU (1) AU2006265216B2 (el)
BR (1) BRPI0612580A8 (el)
CA (1) CA2613059C (el)
CY (1) CY1111627T1 (el)
DE (1) DE502006008392D1 (el)
DK (1) DK1899330T3 (el)
EA (1) EA015188B1 (el)
EC (1) ECSP078058A (el)
ES (1) ES2357029T3 (el)
HK (1) HK1116190A1 (el)
HR (1) HRP20110044T2 (el)
IL (1) IL188323A (el)
MX (1) MX2007016253A (el)
MY (1) MY145883A (el)
NO (1) NO340670B1 (el)
NZ (1) NZ565440A (el)
PE (1) PE20070171A1 (el)
PL (1) PL1899330T3 (el)
PT (1) PT1899330E (el)
RS (1) RS51572B (el)
SG (1) SG163540A1 (el)
SI (1) SI1899330T1 (el)
TW (1) TWI392495B (el)
UA (1) UA94910C2 (el)
WO (1) WO2007003536A1 (el)
ZA (1) ZA200708525B (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2439207A1 (en) 2004-10-04 2012-04-11 Millennium Pharmaceuticals, Inc. Lactam Compounds Useful as Protein Kinase Inhibitors
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
JP2009543812A (ja) * 2006-07-20 2009-12-10 キャスケイド・セラピューティクス・インコーポレイテッド ５−ＨＴ２Ｃリガンドとしてのテトラヒドロ−５Ｈ−ピリド［２，３−ｄ］アゼピン
PE20081834A1 (es) * 2006-12-31 2009-01-16 Boehringer Ingelheim Int Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos
EP1975165A1 (de) 2007-03-27 2008-10-01 Boehringer Ingelheim Pharma GmbH & Co. KG Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel
WO2009063028A2 (en) 2007-11-15 2009-05-22 Boehringer Ingelheim International Gmbh Substituted amides, manufacturing and use thereof as medicaments
US8288397B2 (en) 2007-12-17 2012-10-16 Janssen Pharmaceutica Nv Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
WO2010065134A1 (en) 2008-12-05 2010-06-10 Millennium Pharmaceuticals, Inc. 5, 7-dihydro- 6h-pyrimido [ 5, 4-d] [ 1 ] benzazepin-6-thiones as plk inhibitors
EP2398781A1 (en) * 2009-02-17 2011-12-28 Msd K.K. 1,4-benzodiazepin-2-on derivatives
EP3248615A1 (en) 2010-03-30 2017-11-29 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
EP2758075B1 (en) 2011-09-20 2023-05-03 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
CA2895508A1 (en) 2012-12-18 2014-06-26 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
KR102256242B1 (ko) * 2014-02-07 2021-05-26 엑시테라 파마슈티컬스 인코퍼레이티드 치료 화합물 및 조성물
CN105622511B (zh) * 2014-11-03 2018-01-23 北京瑞都医药科技有限公司 一种减肥药物及其制备方法
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
EP3818050B1 (en) 2018-07-05 2023-05-31 Bayer Aktiengesellschaft Substituted thiophenecarboxamides and analogues as antibacterials agents
CN111196772B (zh) * 2018-11-16 2022-09-30 沈阳化工研究院有限公司 一种芳酰氨基异丁酰衍生物及其应用
CA3165263A1 (en) 2019-12-20 2021-06-24 Bayer Aktiengesellschaft Thienyloxazolones and analogues
CN116406266A (zh) 2020-11-06 2023-07-07 勃林格殷格翰国际有限公司 2-[(噻吩-2-基)甲酰胺基]-n-(苯基)-2-甲基丙酰胺衍生物及其作为药物的用途
WO2025019631A1 (en) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60022508T2 (de) * 1999-06-14 2006-06-08 Eli Lilly And Co., Indianapolis Inhibitoren von serin proteasen
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AP1540A (en) * 2000-03-21 2006-01-11 Smithkline Beecham Corp Protease inhibitors
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
JP2004527575A (ja) * 2001-05-17 2004-09-09 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害物質
JP2004300133A (ja) * 2002-11-19 2004-10-28 Takeda Chem Ind Ltd アミン誘導体
WO2004046107A1 (en) 2002-11-19 2004-06-03 Takeda Pharmaceutical Company Limited Indole derivatives as somatostatin agonists or antagonists
DE10254336A1 (de) 2002-11-21 2004-06-03 Merck Patent Gmbh Carbonsäureamide
US7250415B2 (en) 2003-06-04 2007-07-31 Bristol-Myers Squibb Company 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors
JP2007537181A (ja) * 2004-05-13 2007-12-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換されたチオフェン−カルボン酸アミド、医薬品の形態におけるこれらの製造及び使用
CA2562714A1 (en) 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Substituted thiophene-2-carboxylic acid amides, the production thereof and the use thereof as drugs
EP1747217A1 (de) * 2004-05-13 2007-01-31 Boehringer Ingelheim International GmbH Neue substituierte thiophencarbonsäureamide, deren herstellung und deren verwendung als arzneimittel
DE102004047840A1 (de) 2004-09-29 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Thiophencarbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
PE20081834A1 (es) 2006-12-31 2009-01-16 Boehringer Ingelheim Int Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos

Also Published As

Publication number Publication date
EA200702620A1 (ru) 2008-06-30
BRPI0612580A2 (pt) 2010-11-23
US20100216769A1 (en) 2010-08-26
ZA200708525B (en) 2009-08-26
PT1899330E (pt) 2011-01-11
CN101213195B (zh) 2012-05-09
UA94910C2 (ru) 2011-06-25
CA2613059A1 (en) 2007-01-11
EP1899330B1 (de) 2010-11-24
IL188323A (en) 2013-08-29
ES2357029T3 (es) 2011-04-15
SG163540A1 (en) 2010-08-30
KR20080033318A (ko) 2008-04-16
SI1899330T1 (sl) 2011-03-31
DE502006008392D1 (de) 2011-01-05
US9676781B2 (en) 2017-06-13
HRP20110044T1 (en) 2011-02-28
IL188323A0 (en) 2008-04-13
EP1899330B9 (de) 2011-11-09
MX2007016253A (es) 2008-03-07
RS51572B (en) 2011-08-31
US9062034B2 (en) 2015-06-23
PE20070171A1 (es) 2007-03-08
AU2006265216B2 (en) 2011-09-29
US20150252050A1 (en) 2015-09-10
AR054627A1 (es) 2007-07-04
DK1899330T3 (da) 2011-02-21
HRP20110044T2 (hr) 2012-02-29
PL1899330T3 (pl) 2011-05-31
EA015188B1 (ru) 2011-06-30
ECSP078058A (es) 2008-01-23
WO2007003536A1 (de) 2007-01-11
MY145883A (en) 2012-05-15
HK1116190A1 (en) 2008-12-19
EP1899330A1 (de) 2008-03-19
BRPI0612580A8 (pt) 2017-12-26
CN101213195A (zh) 2008-07-02
NO20075186L (no) 2008-02-14
NZ565440A (en) 2011-04-29
CA2613059C (en) 2013-12-24
ATE489381T1 (de) 2010-12-15
TW200738692A (en) 2007-10-16
NO340670B1 (no) 2017-05-29
JP4768016B2 (ja) 2011-09-07
KR101321722B1 (ko) 2013-10-25
TWI392495B (zh) 2013-04-11
JP2008546741A (ja) 2008-12-25
AU2006265216A1 (en) 2007-01-11
US20130184256A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
CY1111627T1 (el) Υποκατεστημενα γλυκιναμιδια με αντιθρομβωτικη δραση και ανασταλτικη δραση στον παραγοντα χα
CY1112005T1 (el) Νεα καρβοξαμιδια ως αναστολεις του παραγοντα χa
CY1120995T1 (el) Ετεροκυκλικη ενωση και χρηση αυτης
CY1108744T1 (el) 2-οξο-1,2,4,5-τετραϋδρo-1,3-βενζοδιαζεπιν-3-υλ-πιπεριδινες ως ανταγωνιστες της cgrp
CY1109644T1 (el) 2,4-διαμινο-πυριμιδινες ως αναστολεις audora
CY1118717T1 (el) Αναστολεις c-fms κινασης
CY1113767T1 (el) Παραγωγα πυριδινης χρησιμα ως ενεργοποιητες γλυκοκινασης
CY1108183T1 (el) Θειαζολυλο-διυδρο-ινδαζολια
CY1113757T1 (el) Παραγωγα πιπεριδινης και πιπεραζινης για τη θεραπεια ογκων
CY1110835T1 (el) Διφαινυλ παραγωγα και η χρηση τους στη θεραπεια της ηπατιτιδας c
EA200802210A1 (ru) Замещенные пролинамиды, их получение и их применение в качестве лекарственных средств
CY1105797T1 (el) Ν-αρυλ-2-οχαζολιδινονο-5-καρβοξαμιδια και παραγωγα αυτων και χρηση αυτων σαν αντιβιοτικα
CY1111705T1 (el) Παραγωγα 2-αζα-δικυκλο[3.1.0]εξανιου ως ανταγωνιστες του υποδοχεα ορεξινης
UY30979A1 (es) Pirrolidinamidas sustituidas, su preparacion y su uso como medicamentos
ECSP088677A (es) Piperazinas y piperidinas como potenciadores 157 del mglur5
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
CY1114095T1 (el) Μυκητοκτονες συνθεσεις
CY1112886T1 (el) Ανοσοκατασταλτικος παραγοντας ο οποιος περιλαμβανει μια ετεροκυκλικη ενωση ως δραστικο συστατικο
CY1111628T1 (el) Υποκατεστημενες ενωσεις δικυκλολακταμης
CY1113631T1 (el) Παραγωγα σπειροετεροκυκλικης πυρρολιδινο διονης χρησιμα ως ζιζανιοκτονα
CY1109928T1 (el) 8-[3-αμινο-πιπεριδιν-1-υλο]-ξανθινες, παραγωγη αυτων και χρηση τους ως φαρμακων
CY1107149T1 (el) Νεα παραγωγα αμιδινοβενζυλαμινης και χρηση τους ως αναστολεων θρομβινης
ATE435506T1 (de) Konjugierte polymere, deren darstellung und verwendung
TW200700358A (en) Organic compounds
CY1112031T1 (el) Υποκατεστημενη 5-φαινυλο-3,6-διυδρο-2-οξο-6η-[1,3,4]θειαδιαζινη